Genesis Therapeutics
Yongkai Li is an experienced professional in the pharmaceutical and biotechnology sectors, currently serving as Associate Director at Genesis Therapeutics since September 2022. Prior to this role, Yongkai held the position of Associate Director at Zentalis Pharmaceuticals from May 2021 to June 2022. Additionally, Yongkai was a Principal Investigator at Calibr at Scripps Research from January 2020 to May 2021 and worked as a Research Investigator at the Genomics Institute of the Novartis Research Foundation from April 2007 to December 2019. Early career experience includes roles as a Research Scientist at Ligand Pharmaceuticals and as a Postdoc at The Scripps Research Institute. Yongkai Li's academic background includes education from Dartmouth College and Nanjing University.
This person is not in any offices
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.